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Older people are at risk of potentially inappropriate prescribing (PIP) due to polypharmacy arising from 3 
multimorbidity. Despite available explicit criteria to reduce PIP, it is highly prevalent. While commu-4 
nity pharmacists have the required knowledge to help reduce PIP, they are not currently engaged with 5 
the problem. This study explores the views of community pharmacists on their potential involvement 6 
in reducing PIP and determines the challenges to its implementation.  7 
 8 
Methods 9 
Semi-structured interviews with pharmacists working in community pharmacies in Ireland. The Theo-10 
retical Domains Framework (TDF) was used to develop the topic guide and to analyse the transcripts. 11 
Domains of highest relevance for PIP reduction were identified based on their frequency or whether the 12 
participants emphasised the impact of constructs within a domain. Local ethical approval was obtained. 13 
Results 14 
Of 18 participants, 12 were female, median age was 30 years (IQR, 27-35) with a median of 6 years 15 
(IQR 3-8) of experience. Seven TDF domains were identified as relevant to PIP reduction. Pharmacists 16 
were uncertain about their role in reducing PIP and reluctant to challenge physicians’ prescribing deci-17 
sions. Challenges pertained to the environment, knowledge, social influences, professional role and 18 
identity.   19 
Conclusions 20 
Pharmacists welcomed new responsibilities in reducing PIP as part of their daily practice but expressed 21 
a need for removal of social and environmental barriers as well as, provision of relevant guidelines and 22 
education about PIP. This study provides useful insights into the target domains for overcoming barriers 23 
of pharmacist-involvement in reducing PIP. 24 
Keywords 25 
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Introduction  27 
Older multi-morbid people are at substantial risk of having potentially inappropriate prescribing (PIP) 28 
[1,2]. The risk of PIP increases as people grow older and is strongly associated with the higher number 29 
of daily medicines, i.e. polypharmacy, used to treat multi-morbid illness [3-5]. Patient safety is at risk 30 
when older people are exposed to PIP because of the associated adverse drug events (ADEs) and drug-31 
related hospitalisations of PIP [6,7]. Previous studies indicate a high prevalence of PIP throughout the 32 
primary care setting in Ireland, with prevalence estimates of 21-57% [3,5,8,9]. Similar prevalence esti-33 
mates have been reported in the neighbouring country, Northern Ireland (34%) [10] and in other Euro-34 
pean countries, e.g. Spain (38-46% ) [11] and the Netherlands (35- 85%) [4]. No intervention has suc-35 
ceeded in reducing the substantial PIP prevalence in primary care despite the existence of explicit cri-36 
teria to identify PIP for over 10 years, and the evidence that they are effective in reducing PIP in hos-37 
pitalised, older patients [2,4,12]. Two of the most commonly cited sets of PIP criteria are Beers’ criteria 38 
[13-17] and Screening Tool of Older People’s Prescriptions (STOPP) and Screening Tool to Alert to 39 
Right Treatment (START) criteria [1].  There are currently four randomised clinical trials showing the 40 
clinical efficacy of applying STOPP/START criteria to reduce PIP[2,18], falls incidence and overall 41 
medication cost [19], as well as incidence of ADRs [12] in the hospital and nursing home settings.  42 
 Reviewing new and repeat prescriptions and completing medication reviews are recognized 43 
ways of identifying PIP. Medication review is a broad term covering several interventions carried out 44 
by prescribers themselves or by other practitioners providing advice to prescribers (e.g. pharmacists) 45 
with the overall aim of improving the quality, safety and appropriateness of use of medicines [20]. 46 
Studies in primary care settings have demonstrated a significant positive effect of medication reviews 47 
on the reduction of PIP in older people [21-24], and also in community pharmacy settings [24].  Phar-48 
macists are in a position to identify and help reduce PIP. However, prevalence data of PIP among com-49 
munity-dwelling older people indicate that pharmacists are not undertaking this important role of iden-50 
tifiers of PIP with a further remit of PIP prevention [25-27]. 51 
When designing an intervention to change traditional working practice, it is fundamental to 52 
understand the processes underlying the behaviour [28,29]. In the case of pharmacists, it is essential to 53 
understand the barriers and facilitators for the involvement, or lack thereof, of community pharmacists 54 
in reducing PIP. The Theoretical Domains Framework (TDF) was originally  developed by Michie et 55 
al. [30] and later updated by Cane et al. [31]. The TDF considers a wide range of possible theoretical 56 
explanations for the relevant behaviours [28,32,33]. The 12 domain TDF [30] has been widely used in 57 
health research to define behaviours and to identify barriers and facilitators to that behaviour [28,33,34]. 58 
The identification of such domains relevant for a specific behaviour change is an important step in the 59 
design of an intervention [31,35]. In this study, the 14 domain TDF was employed to identify barriers 60 
and facilitators of pharmacist-involvement in reducing PIP. The 14 domain TDF has previously been 61 
used to explore a similar topic: the utilisation of a screening tool in medicines usages reviews (MURs) 62 
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by community pharmacists [35]; and was deemed appropriate to investigate their involvement in reduc-63 
ing PIP.  64 
Whilst large randomised controlled trials are examining various ways to assess the interventions 65 
targeted at prevention of PIP in hospital care settings [2,36,37], little research is being carried out in 66 
primary care.  To date, the views of the community pharmacists on reducing PIP have been given little 67 
attention [35]. Therefore, this study aimed to explore the views of community pharmacists on their 68 
potential involvement in reducing PIP, and to determine the perceived barriers and facilitators to the 69 
implementation of PIP reduction in community pharmacy practice.  70 
Methods 71 
Compliance with Ethical Standards 72 
Ethical approval for this study was granted by the Clinical Research Ethics Committee of the Cork 73 
Teaching Hospitals prior to recruitment. Written informed consent was obtained from all participants 74 
included in the study. 75 
Sampling  76 
Community pharmacists working in community practice in Cork in Ireland were recruited using con-77 
venience sampling based on a sampling matrix. The convenience sampling method was chosen due to 78 
time constrictions of the study and to increase the likelihood of respondents. Hence, a close geographic 79 
proximity allowed the researcher (CH) to conduct face-to-face interviews with participants at suitable 80 
location.  Pharmacies located in Cork were identified and contacted by telephone. The study was intro-81 
duced to the pharmacist on call at that actual time, and the pharmacist was asked to take part in the 82 
study. An agreed interview date, time and location were then arranged. Currently working in community 83 
practice was the only inclusion criterion, and there were no exclusion criteria.  84 
A sampling matrix was designed to ensure variation of important participant characteristics in the study 85 
population (see Online Resource I). The design of the matrix was done by three researchers (CH, LS 86 
and SB) together with a panel of pharmacists with backgrounds in academia and community pharmacy 87 
practice. The final matrix design was approved by all authors. Matrix parameters chosen were: (i) ex-88 
perience from working with nursing homes (either from working in a nursing home or from working in 89 
a pharmacy serving nursing homes), (ii) years of experience working as a community pharmacist (<3 90 
years, ≥3 years and ≥10 years), and (iii) number of pharmacists working simultaneously in the phar-91 
macy. A cut-off of 3 years of community experience was chosen as a matrix parameter because phar-92 
macists in Ireland after a 3-year period can choose to take up employment subsequently as Supervising/ 93 
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Superintendent Pharmacist1. Being a supporting or a supervising pharmacist was considered to influ-94 
ence the level of confidence and knowledge.  A threshold of 10 years or more experience was then 95 
agreed by the authors and the expert panel due to an expected seniority after 10 years which might have 96 
influenced their opinions and answers. Experience of working in a nursing home was considered to 97 
have an influence on the pharmacists’ answers relating to medication reviews and polypharmacy issues 98 
as these are commonly undertaken by pharmacists in Irish nursing homes. The number of registered 99 
pharmacists on duty in the pharmacy at any one time was believed to have an impact on their perceived 100 
capability to perform medication reviews compared to those pharmacies with a single pharmacist on 101 
duty. Although not matrix parameters, the areas in which the pharmacists worked i.e. urban or rural as 102 
well as associated affluence or disadvantage were considered when recruiting. Areas with social afflu-103 
ence and disadvantage were identified from the deprivation index viewer (available from www.pobal.ie) 104 
[38].   105 
Interview topic guide 106 
An interview topic guide (see Online Resource II) was designed to explore the 14 domains of the frame-107 
work [30,31] while also allowing the participants to freely share their opinions. Using the TDF to design 108 
the topic guide is a helpful tool in formulating questions that will enable the identification of the behav-109 
iour and the barriers and facilitators to that behaviour. The use of a TDF-formulated topic guide has 110 
also been shown to effectively elicit responses from the interviewees that they would not otherwise 111 
report [29]. The topic guide was refined by consensus among all authors and with an expert panel of 112 
pharmacists with backgrounds in academia and community pharmacy practice. The topic guide was 113 
pilot tested in two community pharmacists. During the study it was refined on an iterative basis after 114 
each interview was transcribed to allow for emerging themes to be explored in subsequent interviews. 115 
Interviews were conducted until the point of thematic saturation as described by Francis et al. [39]. The 116 
interviews were introduced with some general questions regarding their awareness and beliefs about 117 
PIP and medication reviews. Participants were shown the recently developed deprescribing algorithms 118 
and asked to give their opinion about the content, layout and usefulness in their daily practice [40-43]. 119 
Participant demographic details were also collected including gender, age, number of years of experi-120 
ence in community pharmacy.  121 
Data collection 122 
Semi-structured interviews with pharmacists working in community pharmacies in Ireland conducted 123 
by one researcher (CH). This type of interviews was chosen as it encourages interviewees to share the 124 
                                                          
1 The Supervising/Superintendent pharmacists is the person responsible for the day-to-day management and op-





Page 6 of 19 
 
views and opinions that are important to him/her [44]. Interviews were conducted face-to-face or over 125 
the telephone. At the time of the interviews the participant received an information letter and gave their 126 
written consent. Interviews were audio-recorded and transcribed verbatim. Transcripts were returned to 127 
participants for review, but no one accepted this offer. 128 
Qualitative data analysis  129 
Transcripts were anonymised and transferred to the QSR NVivo® Version 11 software. In line with 130 
framework analysis, a familiarisation process took place whereby the researcher (CH) repeatedly lis-131 
tened to the interview audio-recordings and read the interview transcripts. From the transcribing process 132 
and familiarisation process the researcher (CH) attained an overview of specific beliefs within the data 133 
[45]. Following this step, CH coded excerpts from the interview transcripts into one or more of the 14 134 
TDF domains. Three randomly selected transcripts were coded by a second researcher (LS) to assure 135 
validity and reliability of the data analysis. Disagreement in coding between the two researchers was 136 
resolved through discussion and consensus. Domains for which transcript excerpts were coded into 137 
were summarized by CH. Supporting excerpts were attached to each domain summary. The summaries 138 
were reviewed by LS. The two researchers determined the domains of relevance for PIP reduction using 139 
a similar approach to previous studies [28,35]. A domain was deemed relevant if excerpts were coded 140 
frequently into this or if the participants emphasised the significant impact of barriers and/or facilitators 141 
within a domain on their involvement in reducing PIP.   142 
Results  143 
A total of 21 pharmacists were approached of whom 18 agreed to participate. One pharmacist refused 144 
to participate and the remaining two were unavailable at the time of the study. There were no dropouts 145 
in this study.  Interviews were conducted in the period from June to end of August 2017. The interviews 146 
were a mean length of 19 minutes (SD 6.00) and took place at the pharmacy in which the participant 147 
worked. Data saturation was reached after 15 interviews with no new themes emerging from conducting 148 
an additional three interviews. Characteristics of the participants are described in Text box 1.  149 
[Insert Text box 1] 150 
Pharmacists were familiar with the term ‘inappropriate prescribing’ and defined this as: (i) any 151 
medication prescribed that has the potential to cause harm, side-effects or drug interactions; (ii) over-152 
prescribing or prescribing without a documented indication; (iii) prescribing a medicine to relieve side-153 
effects of another medicine that the patient is taking; (iv) prescribing any medication for longer than 154 
indicated; and (v) prescribing a medicine not suitable for older people. A few pharmacists mentioned 155 
the explicit  STOPP/START criteria [1,46] to identify PIP but the majority referred to treatment guide-156 
lines such as the NICE guidelines [47] and no pharmacist used explicit set of criteria to identify PIP in 157 
their daily work. The pharmacists perceived the presented deprescribing algorithms [40-43] to give a 158 
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good overview and to be user-friendly. However, some pharmacists also believed that the information 159 
on the algorithms was well-known among pharmacists, and did not believe algorithms to have signifi-160 
cant influence on their involvement in reducing PIP. 161 
Pharmacists described medication reviews as the systematic process of reviewing patients’ 162 
medications and identifying drug-related problems. No pharmacist had experience of doing medication 163 
reviews in community pharmacy setting but some had experience from educational sessions or from 164 
working in hospitals or nursing homes. No pharmacist interviewed was carrying out medication reviews 165 
as part of their current routine practice.  166 
Qualitative analysis themes 167 
Transcript excerpts were most frequently coded into five domains: (i) beliefs about capabilities, (ii) 168 
environmental context and resources, (iii) knowledge, (iv) social influences and (v) social professional 169 
role and identity. The two domains memory, attention and decision processes and reinforcement were 170 
less frequently coded. However, those participants who made comments coded into these domains at-171 
tached significant importance to the factors identified. The interview data coded into these seven do-172 
mains are summarized in Table 1 with illustrative quotations. 173 
 Beliefs about capabilities 174 
Pharmacists perceived themselves as appropriate healthcare providers to identify PIP. Competencies 175 
were attributed to: being trained to do it; being good at identifying PIP; having a good relationship with 176 
patients due to the nature of patients visiting their pharmacy more often than their General Practitioner 177 
(GP); and looking at older patients’ prescription drugs with fresh eyes. 178 
Beliefs about capabilities were affected by a pharmacist’s level of confidence and this subse-179 
quently influenced the likelihood of the pharmacist communicating any recommendations to the GP. 180 
One pharmacist’s self-perceived duty as a pharmacist gave her the confidence to act when an instance 181 
of PIP was identified (Table 1). Another, younger pharmacist (1.5 years of experience) described how 182 
her lack of confidence restrained her from actively giving her input despite her beliefs about her role 183 
(Table 1). 184 
Environmental context and resources 185 
Being busy with serving many patients and doing administrative work were believed to restrict time to 186 
do medication reviews and to have follow-up contact with prescribers to discuss potential changes. 187 
Pharmacists described a need to prioritise their time and focus on more immediately unsafe issues, such 188 
as major drug-drug interactions, rather than reviewing medication lists for PIP, which was felt to have 189 
more medium or long-term implications for the patient (Table 1). Protected time to review medications 190 
facilitated by extra pharmacist staff was a suggested solution.  191 
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 Another challenge was a lack of communication between healthcare providers, e.g. between 192 
pharmacists and GPs, and was thought to lead to confusion about medication changes and to impede 193 
the implementation of these changes. Pharmacists described being unsure where the responsibility for 194 
stopping PIP resides. Suggested improvements included more direct lines of communication and will-195 
ingness to collaborate from all parties. Geographic proximity and face-to-face interaction were believed 196 
to be key facilitators of a good collaborative relationship (Table 1).    197 
 Other challenges pertained to a lack of patient information, e.g. diagnosis or indication for a 198 
drug. Receiving hospital discharge letters and gaining access to a centralised clinical record system for 199 
sharing patient information between pharmacists and GPs were suggested improvements.  200 
Knowledge 201 
Pharmacists believed their pharmacology/therapeutics knowledge to be sufficient to identify PIP but 202 
stressed the need for continuing professional education to bring their knowledge in line with new med-203 
ications and most up-to-date guidelines. Interdisciplinary training was suggested as one way to meet 204 
these educational needs whilst simultaneously improving collaboration between pharmacists and GPs 205 
(Table 1).  206 
 Guidelines were perceived to be valuable information sources partly because of their generally 207 
easy application to daily practice and partly for the evidence-base guidance to pharmacists’ recommen-208 
dations. However, some pharmacists criticised guidelines for limitations such as describing how to 209 
identify PIP without specific guidance on how to manage it (Table 1).  210 
Social influences 211 
Patient demands and their relative interest in medication were noted to strongly influence the changing 212 
or discontinuation of medication. Some patients were described as demanding treatment and not being 213 
content to adjust their medication due to fear of change or loyalty to the doctors’ prescription orders 214 
(Table 1). 215 
 Pharmacists also noted however that their regular contact with patients put them in a position 216 
to influence the patients’ behaviours. Pharmacists described how negative interactions with GPs re-217 
sulted in loss of confidence in their own recommendations; conversely, being acknowledged by pa-218 
tients’ GPs motivated pharmacists to discuss potential changes with those GPs (Table 1).  219 
Social professional role and identity 220 
Pharmacists described their current role to include: (a) informing patients about their medication; (b) 221 
maintaining patient safety perspective over financial benefits for the pharmacy; and (c) being familiar 222 
with patients’ particular medication needs. Pharmacists agreed that they had a role in PIP prevention 223 
but were divided regarding the extent to which they should intervene when PIP is detected. A clear 224 
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description of the pharmacist’s role in reducing PIP and an acceptance of this role among healthcare 225 
professionals was suggested as a way in which to increase the involvement of pharmacists (Table 1).  226 
Memory, attention and decision process 227 
Raising awareness of PIP to pharmacists, doctors and patients was thought to enhance PIP reduction. 228 
Suggested initiatives were campaigns from health authorities to patients and/or healthcare providers 229 
(Table 1). The purpose of these campaigns should be to inform patients or GP about particularly prob-230 
lematic drug classes and raise awareness (Table 1).  231 
 Reinforcement 232 
State reimbursement, or professional acknowledgement, for doing medication reviews were both con-233 
sidered to be motivating factors to do medication reviews. However, concerns were raised about the 234 
quality of Government mandatory medication reviews and how incentives may shift focus away from 235 
patient benefits to financial and personal benefits instead.  236 
Discussion  237 
This study used a theoretical approach to explore the views of community pharmacists on their involve-238 
ment in reducing PIP in older people and their perceived barriers and facilitators to this . Despite beliefs 239 
about capability and responsibility for reducing PIP structured medication reviews and recommenda-240 
tions about stopping medications do not form a routine part of daily practice for community pharmacists 241 
in Ireland. It is clear from this study that for some pharmacists there was a sense of conflict in what they 242 
knew to be the identifiable instances of PIP and what they actually did to reduce PIP.  243 
 Pharmacists in expressed uncertainties about the extent of what their role in reducing PIP should 244 
be. They described a reluctance to work outside of their current role and to challenge prescribing deci-245 
sions taken by GPs, such as recommending drug discontinuation. The consequences of this uncertainty 246 
about the pharmacist’s role in patient care, such as reducing PIP, have also been described in the liter-247 
ature [23,26].  In the study by Patterson et al. [23], the inconsistent description of pharmacists’ respon-248 
sibilities in a primary care team was considered to hinder collaboration between pharmacists and other 249 
healthcare professionals. They described how some healthcare professionals felt that pharmacists do 250 
not adequately handle their responsibilities and described a likely relationship between this belief and 251 
a general lack of awareness of the role of the pharmacist [23]. Schindel et al. [26] described how a lack 252 
of consistency in the pharmacy service influences patients’ expectations in that they may be informed 253 
variably about pharmacist services.  254 
 When asked specifically about stopping medications, pharmacists in our study described un-255 
certainty of where final responsibility for PIP avoidance lies. In a recent review, this same theme caused 256 
confusion for GPs and also differing opinions of GPs regarding pharmacist support [48]. Extending the 257 
role of the pharmacist to include patient care may therefore require a clear description of the tasks and 258 
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responsibilities expected to be undertaken by pharmacists that this is clearly communicated to all stake-259 
holders. 260 
 Our findings suggest a need for a shared goal of medicines optimisation, and that by having 261 
more interdisciplinarity within training in medication reviews, this may be achieved. Consistent with 262 
our findings, the study by Patterson et al. [23]  described that collaboration between pharmacists and 263 
GPs was challenged by (i) a lack of understanding of each other’s professional role in combination with 264 
(ii) the busy professional practice environment and (iii) the absence of a shared platform with patient 265 
information. To date, there is no centralised system in which patient information is shared between 266 
community pharmacies and GP practices in the Republic of Ireland. It would be reasonable to suggest 267 
that having access to diagnoses and co-morbidities would increase the clinical relevance of pharmacist 268 
recommendations and improve communications with other healthcare providers.  Sharing patient clin-269 
ical data was suggested in our study as one fundamentally important way to improve communication 270 
and collaboration between community pharmacists and GPs. This was also suggested in the study by 271 
Bergman et al. [25] as a mean of improving satisfaction among some GPs with pharmacist recommen-272 
dations, which were often criticised for lacking consideration of patient context. Keller et al. [27] also 273 
showed how shared patient information enhanced the communication between pharmacists and physi-274 
cians and increased mutual professional trust between them.  275 
 Pharmacists in the present study welcomed more education and guidelines on reducing PIP. 276 
These guidelines should ideally: give instructions on the steps following the identification of a PIP; be 277 
up-to-date; and be used by all, including prescribers. To date, guidelines on stopping inappropriate 278 
medications in older people have been criticised for being too disease-specific and not addressing the 279 
steps of stopping and/or changing a medication identified as inappropriate [48-50].  There is a need to 280 
design guidelines that meet the needs of healthcare professionals in busy medical and pharmacy clinical 281 
practice in terms of content, instructions and relevance. The existing Beers’ criteria and the 282 
STOPP/START criteria as well as the recently developed deprescribing guidelines and algorithms by 283 
Farrell et al. [40,43], Bjerre et al. [41] Pottie et al. [42], Reeve et al. [51] and the newly developed 284 
STOPP Frail criteria [52] may meet these criteria. However, a recent study by Cardwell et al. [35] has 285 
highlighted a number of barriers to the utilisation of screening tools by community pharmacist in daily 286 
practice - those barriers being similar to those of this study. Future investigation on the application of 287 
these deprescribing guidelines in primary care setting is thus warranted and may provide useful insights 288 
into the implementation of more deprescribing to reduce PIP in primary care.   289 
  Whilst some studies to date have shown a positive impact of pharmacist involvement in reduc-290 
ing PIP in primary care [21], more research is needed into the effective implementation of such inter-291 
ventions. The majority of barriers and facilitators identified in this study fall under the TDF domains 292 
of: environment, knowledge; and social professional role and social influences. The design of future 293 
interventions should target these domains. Our findings suggest that future research should focus on the 294 
creation of guidelines that suit the primary care setting as well as investigating new strategies to improve 295 
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the collaboration and communication between healthcare professionals both across and within care set-296 
tings. Policy makers and the educational sector, such as Universities, could support the work of com-297 
munity pharmacists in preventing PIP by offering continuous training and encouraging interprofessional 298 
education, whilst also researching new ways of making more patient-specific information available to 299 
the pharmacist.  300 
 A strength of this study is its use of a robust theoretical framework to analyse the interview 301 
data. Using the TDF ensures that a large variety of factors on behaviour are considered compared to a 302 
more restricting set of factors being explored when using individual theories of behaviour change [35]. 303 
The use of TDF allows the mapping of findings to theory and is a useful way of identifying mediators 304 
of change. Although the use of a pre-specified framework to develop the interview topic guide and to 305 
analyse the data can prevent the emergence of non-predefined themes of relevance, nevertheless the 306 
TDF has been applied successfully in previous studies to describe topics similar to this study [28,33-307 
35]. This study was not without limitations. The sample size of 18, although acceptable for qualitative 308 
research, is small. The nature of qualitative analysis is subjective and despite the use of a sampling 309 
matrix to recruit participants, the findings of this study, as with any qualitative research, are not gener-310 
alisable to all community pharmacists. Additionally, the convenience sampling methods has its limita-311 
tions to the generalisability of the study population, and the self-selected study population may have 312 
introduced self-selection biases. However, the findings of this study may still be relevant to healthcare 313 
providers in other countries.  314 
 In conclusion, pharmacists were generally aware of PIP in older people and its related problems. 315 
Pharmacists mostly welcomed responsibilities into their involvement of reducing PIP but described 316 
challenges of overcoming social and environmental barriers, compounded by a lack of relevant guide-317 
lines for reducing PIP and education on the subject of PIP. This study identified barriers and facilitators 318 
of more pharmacist-involvement in reducing PIP in community practice. The findings pointed to the 319 
need for greater collaboration between physicians and pharmacists in reducing PIP through clearer de-320 
scriptions and mutual awareness of their individual roles and responsibilities in this process. This study 321 
provides useful insights into the target domains for overcoming barriers of pharmacist-involvement in 322 
reducing PIP in community practice and may prove useful in the design of future pharmacist-led inter-323 
ventions to reduce PIP. Although exclusive to Irish community pharmacists, the findings may be of use 324 
in the expansion of the role of the community pharmacist in other countries.   325 
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Text box 1: Characteristics of interview participants (N = 18) 494 
• Community pharmacists interviewed worked in pharmacies placed in urban (n=15) and rural 
(n=3) areas, of which 13 areas were categorised as affluent and 5 were deprived areas ac-
cording to data from www.pobal.ie. 
• 12 female and 6 male pharmacists were interviewed and were a median age of 30 years (Inter 
Quartile Range, IQR 27-35).  
• The pharmacists had a median of 6 years of experience from working in a community phar-
macy (IQR 3-8) and 8 pharmacists had experience from working in or for a nursing home. 
Seven pharmacists had graduated before 2010 and 11 pharmacists after 2010.  
• Eight pharmacists were working in a pharmacy with only one licensed pharmacist and 10 
pharmacists worked in a pharmacy with 2 or more licensed pharmacists on duty. 16 pharma-
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Table 1 Interview quotations supporting the individual theoretical domains identified as relevant for PIP prevention in primary care 499 
TDF domain  Supporting quotes 
Beliefs about  
capabilities 
 “I wouldn’t go down the route and ring up a doctor and saying: ‘You shouldn’t be on this’. The patient has been on this for 
longer than two weeks, you shouldn’t be giving this anymore’. I just don’t. That is probably my role to some extent but I wouldn’t 
like going down that route of complaining to another healthcare professional about what they are doing, so.” [Pharmacist 6, 
Code: Beliefs about capabilities]. “I’d be fairly confident. I’d be kind of, just thinking in my own head: ‘Look, I have a duty of 
care’ and if the doctors are a little bit annoyed with me, I’ll take that.” [Pharmacist 17, Code: Beliefs about capabilities]. “I 
would be happy enough to have a look through somebody’s medicine, if you’re given a bit of time to go through it beforehand. 
Instead of the cuff kind of walking off the street: ‘Oh here’s my 42 medicines in a brown paper bag’(...) But if you have time to 
go through stuff beforehand and had a bit of time to spend with the patient then definitely I think it would be both cost-effective 
and much, much more beneficial to the patient in the long term.” [Pharmacist 18, Code: Beliefs about capabilities]. 
Environmental context 
and resources 
 “I think communication is a huge issue because (…) if something [prescription] comes out from the hospital, the GP might not 
want to stop it. You know the hospital’s intention might have been ‘let’s go on this for 6 weeks’. But then the GP puts it on the 
repeat and then it comes to the pharmacist and I’m looking at it and they’ve been on it for two months. I’m not going to ring the 
GP after two months and say ‘oh, it’s probably inappropriate for you to stop this now’. It’s kind of like who actually [should 
tackle instances of PIP], and where does the buck stop. Who should say ‘this is where it stops’ or ‘this is where it starts’ or.” 
[Pharmacist 15, Code: Environment] “Well it’s just, I guess, everybody’s busy. Ehm, things maybe aren’t reviewed as often as 
they should bet (…). So, you know, it doesn’t, it it just flies by and you know, you’ve got a number of other reasons, which are far 
more immediate in terms of inappropriate prescribing, that you need to look out for. So, you know, those are the ones that you’re 
gonna go for, the ones that are immediately unsafe, I guess.” [Pharmacist 2, Code: Environment] “I suppose between the doc-
tor and the pharmacist. It’s a two-way thing. There needs to be better relationship, I suppose, between the prescribing doctor 
and the pharmacist. Then again, I think it just depends on which doctor you talk to. Some of them are happy about engaging with 
the pharmacist and some of them aren’t. Some don’t want to, so. I suppose, so.” [Pharmacist 16, Code: Environment] 
Knowledge “I think interdisciplinary training would be very good. Get all the GPs and all the pharmacists into the room. Get a little bit of a 
talk, a lecture, have a dinner, and let them [GPs] understand how we [pharmacists] work and the position that we are in, be-
cause we [GPs and pharmacists] often don’t understand our jobs and they can explain. I mean we [pharmacists] go to visit the 
GP for our own thing. So, we kind of have a little bit more of an understanding [of the GP’s work]. But they [GPs] may ever 
come to a pharmacy and they may not know how we operate.” [Pharmacist 12, Code: Knowledge] “Maybe if there was some 
sort of training about how to review those [PIP] that would be good. (…) and some sort of training so then it makes us aware 
that ‘right, we’re going to look out for’ you know” [Pharmacist 9, Code: Knowledge and Memory, attention and decision] 
“It is useful [deprescribing algorithms] but like at the same time like I feel like it’s something that we all already know (…) I 
don’t think it’s the spotting is the big problem. It’s the like what do you do when you do spot it? So, it’s the training of what are 
we actually supposed to do. So, I suppose you do spot it but like I don’t necessarily know like what you’re supposed to do with 
it.” [Pharmacist 15, Code: Knowledge] 
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Social influences   “I suppose for our part it’s just time and for the patient’s part it’s just the interest in it. ….. There are some patients who want 
to know everything that they’re on and every reason. And then other patients who genuinely …..have great belief in the doctor 
and pharmacist and they just think if they were ever prescribed [any medication] they need to take it.” [Pharmacist 13, code: 
Social influences] “A lot of it is: ‘well, if the doctor said’ or ‘if you said’ or you know, someone else said. They don’t kind of 
listen to themselves or do what they think they should do or what as I say, that maybe they are not informed enough.” [Pharma-
cist 17, Code: Social influences] “I sometimes, depending on the doctor, encourage the patient to go back and ask. If you just 
say to the doctor, eh to the patient: ‘maybe say to the doctor ehm could you check your levels’. So, like you say it in a nice way 
so they don’t go like ‘well the pharmacist said’. But you know that they kind of think themselves and maybe they should be ques-
tioning it. You’re kind of empowering them a bit.” [Pharmacist 5, Code: Social influences] Sometimes it, it can be quite diffi-
cult as a pharmacist to deal with certain doctors or certain doctors in the hospitals. Not for the fact that they are authoritarian 
or anything like that but it’s that they’re busy too. They just don’t want the hassle of it. They’re the almighties sometimes (…) 
The channels need to be a bit more open. Sometimes they’re very closed and if they [the doctors] were a bit more open and a bit 
more receptive to what our [pharmacists] role as like a professional could be. Which I think some, some of them aren’t, then I 
think it would help a lot.” [Pharmacist 18, Code: Environment] 
Social professional 
role and identity 
“We should be doing more but we’re doing less [to reduce PIP than we should]. Whether that’s business or whether that’s some 
people are… shying away from it because they’re afraid that they’re out of touch, [such as some] older pharmacists. I’m not 
sure, but definitely there’s this un-realisation of what our role should be in [reducing PIP] for sure.” [Pharmacist 18, code: 
Social/Professional role] “I think it’s, the overall responsibility I think is a two-way think. I think it’s between the GP and phar-
macy, and I don’t think either holds the overall responsibility (…) I suppose we wouldn’t review. I wouldn’t see it as a role, no. 
As a primary role. It would only be if there was an issue with the prescription or if there was an interaction [that the pharmacist 
would contact the prescriber]. But other than that I wouldn’t, no.” [Pharmacist 3, Code: Soc. Prof. role] “I take an active in-
terest into the medication. I’ve no problems ringing a doctor about anything, any time. Even if it’s something small if I think it’s 
gonna benefit the patient. Within reason. I’m not going to be annoying them without reason over stuff either. You know. I always 
try to put patient benefit over profit first.” [Pharmacist 5, Code: Soc. Prof. role] 
Memory, attention and 
decision processes 
“Well those IPU [Irish Pharmacy Union] and HSE [Health Services Executive] campaigns about generic medications for exam-
ple, have been very successful. I think a similar campaign along the lines of ‘do you need everything you’re taking?’. Or encour-
aging patients to go to their doctor. I think to a certain extent; the prescription levy did this very well. Where people went to their 
doctor and asked ‘do I really need to be taking all this?’” [Pharmacist 10, Code: Memory, attention & decision process] 
“Probably advertising it a bit more in so that, and even advertising it in doctor surgeries. Cause I did have someone ask me be-
fore about a person that could do, a certain doctor that would do a medication review, and I was pretty confused, and I said ‘but 
you know that everyone doctors and pharmacists can do it?’. But they’d heard from one person that there was this one doctor 
that does medication reviews and that was the answer. So, I suppose maybe it’s not advertised as a service or advertised as 
something that people can, pharmacists and doctors can do.” [Pharmacist 6, code: Memory, attention & decision process] 
“Well definitely there was one GP, when it all came out [regulations on benzodiazepine prescribing in Ireland], kind of con-
tacted us and said: ‘how am I? Like, am I prescribing more benzodiazepines than any other GP?’. And like that’s an interesting 
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one. Just to be able to say like, on a scale you are prescribing more. It might kind of open their eyes up a little (...) It would be 
hard, but it would be a nice study for someone to do at some stage. To say: ‘look, as a GP you are prescribing this amount as 
opposed to the national average of such and such’.” [Pharmacist 11, code: Memory, attention & decision process] 
Reinforcement “I suppose it’s [PIP] a bit under the radar in a lot of my daily work because you’re not incentivised to look for it (...) Well it’s 
really a case of your incentives. You know, you’re not incentivised to do it. It doesn’t really benefit you directly at all.” [Phar-
macist 2, Code: Reinforcement] “If it [medication reviews] could be incorporated into your CPD [continuing professional 
development], I know pharmacists who would be much more inclined to do it because we’re all trying to clock up our CPD 
hours (…) it should be a thing that if you do your certain medicine reviews you can log this as CPD. You know that the PSI [the 
Pharmaceutical Society of Ireland], or the IPU would support us in that way. The IPU [Irish Pharmacy Union], support us in 
that way and encourage us.” [Pharmacist 5, Code: Reinforcement] “But I think if you try and force people to do it [medication 
reviews] for even for like a financial thing. Reimbursement or anything like this, it’s just going to come to like the same thing as 
we do with say the HSE claims or something. Say, you’re doing it for the wrong reasons and even in that case you mightn’t do it 
properly.” [Pharmacist 7, Code: Reinforcement] 
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